A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT ID: NCT06623422
Last Updated: 2026-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
680 participants
INTERVENTIONAL
2024-10-21
2038-01-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02220894
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
NCT03664024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Intismeran autogene
For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).
Pembrolizumab
IV Infusion
Cisplatin
IV infusion
Carboplatin
IV infusion
Pemetrexed
IV infusion
Gemcitabine
IV infusion
Paclitaxel
IV infusion
Intismeran autogene
IM injection
Pembrolizumab + Placebo
For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\^2, gemcitabine 1000 mg/m\^2, paclitaxel 175 mg/m\^2 or 200 mg/m\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \~42 weeks).
Pembrolizumab
IV Infusion
Cisplatin
IV infusion
Carboplatin
IV infusion
Pemetrexed
IV infusion
Gemcitabine
IV infusion
Paclitaxel
IV infusion
Placebo
IM injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
IV Infusion
Cisplatin
IV infusion
Carboplatin
IV infusion
Pemetrexed
IV infusion
Gemcitabine
IV infusion
Paclitaxel
IV infusion
Intismeran autogene
IM injection
Placebo
IM injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention
* Participants who have not achieved a pathological complete response (pCR) following completion of neoadjuvant chemotherapy and pembrolizumab followed by surgery will be eligible
* Confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations \[eg, DEL19 or L858R\])
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
Exclusion Criteria
* Documentation by local test report indicating presence of anaplastic lymphoma kinase (ALK) gene rearrangements
* Received prior neoadjuvant therapy for their current NSCLC diagnosis
* Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein \[CTLA-4\], OX-40, CD137)
* Received prior systemic anticancer therapy including investigational agents other than what is specified in this protocol
* Received prior treatment with a cancer vaccine
* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ModernaTX, Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center ( Site 0181)
Gilbert, Arizona, United States
The University of Arizona Cancer Center - North Campus ( Site 0163)
Tucson, Arizona, United States
Providence St. Jude Medical Center ( Site 0106)
Fullerton, California, United States
VA Long Beach Healthcare System ( Site 0199)
Long Beach, California, United States
USC Norris Comprehensive Cancer Center ( Site 0205)
Los Angeles, California, United States
UCSF Medical Center at Mission Bay ( Site 0178)
San Francisco, California, United States
University of Colorado Anschutz Medical Campus ( Site 0151)
Aurora, Colorado, United States
UCHealth Memorial Hospital Central ( Site 0125)
Colorado Springs, Colorado, United States
Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207)
Greeley, Colorado, United States
Centura Health - St. Anthony North Health Campus ( Site 0189)
Westminster, Colorado, United States
Yale University School of Medicine ( Site 0201)
New Haven, Connecticut, United States
Eastern CT Hematology & Oncology Associates ( Site 0202)
Norwich, Connecticut, United States
The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156)
Fort Lauderdale, Florida, United States
Beacon Cancer Care ( Site 0127)
Post Falls, Idaho, United States
The University of Chicago Medical Center ( Site 0118)
Chicago, Illinois, United States
Maryland Oncology Hematology (MOH) ( Site 8102)
Rockville, Maryland, United States
Massachusetts General Hospital ( Site 0136)
Boston, Massachusetts, United States
Dana Farber Cancer Hospital ( Site 0155)
Boston, Massachusetts, United States
Ellis Fischel Cancer Center ( Site 0133)
Columbia, Missouri, United States
Lake Regional Hospital-Cancer Center ( Site 0123)
Osage Beach, Missouri, United States
Roswell Park Cancer Institute ( Site 0184)
Buffalo, New York, United States
Hematology-Oncology Associates of CNY ( Site 0164)
East Syracuse, New York, United States
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216)
New York, New York, United States
Icahn School of Medicine at Mount Sinai ( Site 0116)
New York, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 0137)
New York, New York, United States
SUNY Upstate Cancer Center ( Site 0140)
Syracuse, New York, United States
Montefiore Medical Center ( Site 0160)
The Bronx, New York, United States
Westchester Medical Center ( Site 0196)
Valhalla, New York, United States
Novant Health Weisiger Cancer Insititute ( Site 0266)
Charlotte, North Carolina, United States
Novant Health Forsyth Medical Center ( Site 0166)
Winston-Salem, North Carolina, United States
University of Cincinnati Medical Center ( Site 0119)
Cincinnati, Ohio, United States
St. Lukes Hospital and Health Network ( Site 0186)
Bethlehem, Pennsylvania, United States
Thompson Cancer Survival Center ( Site 0168)
Knoxville, Tennessee, United States
Elliston Place Medical Oncology & Hematology ( Site 0215)
Nashville, Tennessee, United States
Texas Oncology - DFW ( Site 8103)
Dallas, Texas, United States
UT Southwestern Medical Center ( Site 0190)
Dallas, Texas, United States
Houston Methodist Cancer Center ( Site 0191)
Houston, Texas, United States
MD Anderson Cancer Center ( Site 0150)
Houston, Texas, United States
Memorial Hermann Cancer Center ( Site 0172)
Houston, Texas, United States
Michael E. DeBakey VA Medical Center ( Site 0197)
Houston, Texas, United States
O'Quinn Medical Tower at McNair Campus ( Site 0131)
Houston, Texas, United States
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148)
Tyler, Texas, United States
Virginia Cancer Specialists ( Site 0167)
Fairfax, Virginia, United States
Virginia Oncology Associates (VOA) ( Site 8101)
Norfolk, Virginia, United States
VCU Health Adult Outpatient Pavillion ( Site 0193)
Richmond, Virginia, United States
Swedish Cancer Institute ( Site 0143)
Seattle, Washington, United States
Virginia Mason Franciscan Health - St. Michael Cancer Center ( Site 0192)
Silverdale, Washington, United States
CEMIC ( Site 2454)
Caba., Buenos Aires, Argentina
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2459)
Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina
Fundacion Intecnus ( Site 2456)
Bariloche, Río Negro Province, Argentina
Centro Médico IPAM ( Site 2452)
Rosario, Santa Fe Province, Argentina
Instituto Medico Especializado Alexander Fleming ( Site 2457)
Buenos Aires, , Argentina
Instituto Oncologico de Cordoba -IONC ( Site 2455)
Córdoba, , Argentina
Calvary Mater Newcastle ( Site 2106)
Waratah, New South Wales, Australia
Tasman Oncology Research ( Site 2104)
Southport, Queensland, Australia
Princess Alexandra Hospital ( Site 2102)
Wooloongabba, Queensland, Australia
Grampians Health ( Site 2101)
Ballarat, Victoria, Australia
One Clinical Research ( Site 2103)
Nedlands, Western Australia, Australia
Cliniques Universitaires Saint-Luc ( Site 1203)
Brussels, Bruxelles-Capitale, Region de, Belgium
Jessa Ziekenhuis ( Site 1204)
Hasselt, Limburg, Belgium
UZ Gent ( Site 1201)
Ghent, Oost-Vlaanderen, Belgium
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 2502)
Fortaleza, Ceará, Brazil
Liga Norte Riograndense Contra o Cancer ( Site 2513)
Natal, Rio Grande do Norte, Brazil
Hospital Tacchini ( Site 2506)
Bento Gonçalves, Rio Grande do Sul, Brazil
Hospital de Clínicas de Passo Fundo ( Site 2504)
Passo Fundo, Rio Grande do Sul, Brazil
Hospital Moinhos de Vento ( Site 2510)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora Da Conceicao ( Site 2512)
Porto Alegre, Rio Grande do Sul, Brazil
Instituto de Oncologia Saint Gallen ( Site 2507)
Santa Cruz do Sul, Rio Grande do Sul, Brazil
Hospital de Amor - Barretos ( Site 2511)
Barretos, São Paulo, Brazil
Instituto Nacional de Câncer - INCA ( Site 2501)
Rio de Janeiro, , Brazil
MBAL Uni Hospital ( Site 1253)
Panagyurishte, Pazardzhik, Bulgaria
MHAT - Heart and Brain ( Site 1252)
Pleven, , Bulgaria
Queen Elizabeth II Health Sciences Centre ( Site 1101)
Halifax, Nova Scotia, Canada
Hamilton Health Sciences - Juravinski Site ( Site 1104)
Hamilton, Ontario, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1105)
Kingston, Ontario, Canada
Lakeridge Health ( Site 1107)
Oshawa, Ontario, Canada
Sunnybrook Research Institute ( Site 1106)
Toronto, Ontario, Canada
McGill University Health Centre ( Site 1103)
Montreal, Quebec, Canada
IUCPQ ( Site 1112)
Québec, Quebec, Canada
Orlandi Oncologia ( Site 2555)
Santiago, Region M. de Santiago, Chile
FALP ( Site 2551)
Santiago, Region M. de Santiago, Chile
Clínica RedSalud Vitacura ( Site 2556)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 2552)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS ( Site 2554)
Viña del Mar, Región de Valparaíso, Chile
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2603)
Bogotá, Bogota D.C., Colombia
Hospital Universitario San Ignacio ( Site 2610)
Bogotá, Bogota D.C., Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 2604)
Bogotá, Bogota D.C., Colombia
IMAT S.A.S ( Site 2602)
Montería, Departamento de Córdoba, Colombia
Oncologos del Occidente ( Site 2608)
Pereira, Risaralda Department, Colombia
Fundacion Valle del Lili- CIC ( Site 2601)
Cali, Valle del Cauca Department, Colombia
Oulun yliopistollinen sairaala ( Site 1301)
Oulu, Northern Savonia, Finland
Turku University Hospital ( Site 1303)
Turku, Southwest Finland, Finland
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau ( Site 1354)
Tours, Centre-Val de Loire, France
CHU Besançon ( Site 1358)
Besançon, Franche-Comte, France
Institut De Cancerologie De L Ouest ( Site 1357)
Saint-Herblain, Loire-Atlantique, France
Institut Cœur Poumon -CHU Lille ( Site 1352)
Lille, Nord, France
CENTRE LEON BERARD ( Site 1351)
Lyon, Rhone, France
Gustave Roussy ( Site 1353)
Villejuif, Île-de-France Region, France
Thoraxklinik-Heidelberg gGmbH ( Site 1412)
Heidelberg, Baden-Wurttemberg, Germany
Robert-Bosch-Krankenhaus ( Site 1401)
Stuttgart, Baden-Wurttemberg, Germany
Klinikverbund Allgäu gGmbH ( Site 1408)
Kempten (Allgäu), Bavaria, Germany
UKGM Gießen/Marburg ( Site 1404)
Giessen, Hesse, Germany
Pius Hospital Oldenburg ( Site 1407)
Oldenburg, Lower Saxony, Germany
St.-Antonius-Hospital ( Site 1411)
Eschweiler, North Rhine-Westphalia, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus ( Site 1405)
Münster, North Rhine-Westphalia, Germany
Marienhaus Klinikum Mainz ( Site 1403)
Mainz, Rhineland-Palatinate, Germany
UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1452)
Pátrai, Achaia, Greece
Errikos Dunant Hospital Center ( Site 1457)
Athens, Attica, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1451)
Athens, Attica, Greece
Metropolitan Hospital ( Site 1459)
Athens, Attica, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1460)
Chaïdári, Attica, Greece
University General Hospital of Herakleion ( Site 1458)
Heraklion, Irakleio, Greece
University General Hospital of Larissa-Oncology Clinic ( Site 1453)
Larissa, Thessaly, Greece
Papageorgiou General Hospital of Thessaloniki ( Site 1454)
Thessaloniki, , Greece
Fejér Megyei Szent György Egyetemi Oktató Kórház ( Site 1506)
Székesfehérvár, Fejér, Hungary
Petz Aladár Megyei Oktató Kórház ( Site 1502)
Győr, Győr-Moson-Sopron, Hungary
Debreceni Egyetem Altalanos Orvostudomanyi Kar Tudogyogyaszati Tanszek ( Site 1508)
Debrecen, Hajdú-Bihar, Hungary
Mátrai Gyógyintézet ( Site 1504)
Mátraháza, Heves County, Hungary
Reformatus Pulmonologiai Centrum-Onkopulmonologiai Jarobeteg Centrum ( Site 1505)
Törökbálint, Pest County, Hungary
Somogy Vármegyei Kaposi Mór Oktató Kórház-Oncology center ( Site 1507)
Kaposvár, Somogy County, Hungary
Orszagos Koranyi Pulmonologiai Intezet ( Site 1501)
Budapest, , Hungary
Cork University Hospital ( Site 1553)
Cork, , Ireland
St. James's Hospital ( Site 1554)
Dublin, , Ireland
Tallaght University Hospital ( Site 1551)
Dublin, , Ireland
Rambam Health Care Campus ( Site 1603)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 1601)
Jerusalem, , Israel
Hadassah Medical Center ( Site 1605)
Jerusalem, , Israel
Meir Medical Center ( Site 1606)
Kfar Saba, , Israel
Sheba Medical Center ( Site 1602)
Ramat Gan, , Israel
AOU Renato Dulbecco ( Site 1661)
Catanzaro, Calabria, Italy
Ospedale Santa Maria delle Croci ( Site 1652)
Ravenna, Emilia-Romagna, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1653)
Rome, Lazio, Italy
Fondazione Policlinico Universitario Campus Bio-Medico ( Site 1660)
Rome, Roma, Italy
Istituto Nazionale Tumori Regina Elena ( Site 1651)
Rome, Roma, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1656)
Milan, , Italy
IEO Istituto Europeo di Oncologia ( Site 1655)
Milan, , Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1657)
Napoli, , Italy
IRCCS Istituto Oncologico Veneto ( Site 1654)
Padua, , Italy
Centro Ricerche Cliniche di Verona ( Site 1659)
Verona, , Italy
Hospital of the University of Occupational and Environmental Health, Japan ( Site 1166)
Kitakyushu, Fukuoka, Japan
St. Marianna University Hospital ( Site 1159)
Kawasaki, Kanagawa, Japan
Kanagawa Cancer Center ( Site 1158)
Yokohama, Kanagawa, Japan
Kindai University Hospital ( Site 1162)
Sakai, Osaka, Japan
Shizuoka Cancer Center ( Site 1160)
Sunto-gun, Shizuoka, Japan
Dokkyo Medical University Hospital ( Site 1152)
Shimotsuga-gun, Tochigi, Japan
National Cancer Center Hospital ( Site 1156)
Chūō, Tokyo, Japan
Tokyo Medical University Hospital ( Site 1157)
Shinjuku, Tokyo, Japan
Chiba University Hospital ( Site 1154)
Chiba, , Japan
National Hospital Organization Kyushu Cancer Center ( Site 1167)
Fukuoka, , Japan
Fukushima Medical University Hospital ( Site 1151)
Fukushima, , Japan
Hiroshima University Hospital ( Site 1165)
Hiroshima, , Japan
Okayama University Hospital ( Site 1164)
Okayama, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 1161)
Osaka, , Japan
Wakayama Medical University Hospital ( Site 1163)
Wakayama, , Japan
Radboudumc ( Site 1706)
Nijmegen, Gelderland, Netherlands
Maastricht UMC+ ( Site 1705)
Maastricht, Limburg, Netherlands
Jeroen Bosch Hospital ( Site 1701)
's-Hertogenbosch, North Brabant, Netherlands
Medisch Centrum Leeuwarden ( Site 1702)
Leeuwarden, Provincie Friesland, Netherlands
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 2201)
Tauranga, Bay of Plenty, New Zealand
Dunedin Hospital ( Site 2202)
Dunedin, Otago, New Zealand
Waikato Hospital ( Site 2204)
Hamilton, Waikato Region, New Zealand
Aliada ( Site 2753)
Lima, , Peru
Clínica Internacional - Sede San Borja ( Site 2752)
Lima, , Peru
Detecta Clínica ( Site 2751)
Lima, , Peru
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1763)
Poznan, Greater Poland Voivodeship, Poland
Krakowski Szpital Specjalistyczny im. Jana Pawla II ( Site 1756)
Krakow, Lesser Poland Voivodeship, Poland
Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 1764)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1759)
Przemyśl, Podkarpackie Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne ( Site 1758)
Gdansk, Pomeranian Voivodeship, Poland
Warmińsko - Mazurskie Centrum Chorób Płuc w Olsztynie ( Site 1760)
Olsztyn, Warmian-Masurian Voivodeship, Poland
Swietokrzyskie Centrum Onkologii. ( Site 1754)
Kielce, Świętokrzyskie Voivodeship, Poland
Centrul Medical Medicover Victoria ( Site 1802)
Bucharest, București, Romania
Cabinet Medical Oncomed ( Site 1803)
Timișoara, Timiș County, Romania
Institutul Regional de Oncologie ( Site 1804)
Iași, , Romania
National Cancer Centre Singapore ( Site 2251)
Singapore, Central Singapore, Singapore
Tan Tock Seng Hospital ( Site 2252)
Singapore, Central Singapore, Singapore
National Cancer Center ( Site 2305)
Goyang-si, Kyonggi-do, South Korea
The Catholic University of Korea St. Vincent s Hospital ( Site 2301)
Suwon, Kyonggi-do, South Korea
Ajou University Hospital ( Site 2306)
Suwon, Kyonggi-do, South Korea
Seoul National University Hospital ( Site 2303)
Seoul, , South Korea
Severance Hospital Yonsei University Health System ( Site 2302)
Seoul, , South Korea
Samsung Medical Center ( Site 2304)
Seoul, , South Korea
Seoul St. Mary's Hospital ( Site 2307)
Seoul, , South Korea
Hospital Insular de Gran Canaria ( Site 1911)
Canarias, Canary Islands, Spain
Hospital Clinic de Barcelona ( Site 1919)
Barcelona, Catalonia, Spain
Complejo Hospitalario Universitario A Coruna ( Site 1916)
A Coruña, La Coruna, Spain
Hospital Universitario Quiron Madrid ( Site 1913)
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitari Vall D Hebron ( Site 1910)
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon ( Site 1912)
Madrid, , Spain
Hospital Quiron Malaga ( Site 1914)
Málaga, , Spain
Karolinska Universitetssjukhuset Solna ( Site 1951)
Stockholm, Stockholm County, Sweden
Chung Shan Medical University Hospital ( Site 2351)
Taichung, , Taiwan
China Medical University Hospital ( Site 2358)
Taichung, , Taiwan
National Cheng Kung University Hospital ( Site 2354)
Tainan, , Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 2360)
Taipei, , Taiwan
Mackay Memorial Hospital ( Site 2355)
Taipei, , Taiwan
Taipei Medical University Hospital ( Site 2352)
Taipei, , Taiwan
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2359)
Taipei, , Taiwan
Taipei Veterans General Hospital ( Site 2357)
Taipei, , Taiwan
Chang Gung Memorial Hospital ( Site 2361)
Taoyuan District, , Taiwan
Ramathibodi Hospital ( Site 2405)
Ratchathewi, Bangkok, Thailand
Faculty of Medicine - Khon Kaen University ( Site 2401)
Muang, Changwat Khon Kaen, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 2404)
Muang, Chiang Mai, Thailand
Hacettepe Universite Hastaneleri ( Site 2001)
Sıhhiye, Ankara, Turkey (Türkiye)
Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 2006)
Adapazarı, Sakarya, Turkey (Türkiye)
Namık Kemal University Medical Faculty ( Site 2007)
Tekirdağ, Tekirdas, Turkey (Türkiye)
Ankara Bilkent Sehir Hastanesi ( Site 2002)
Ankara, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 2003)
Istanbul, , Turkey (Türkiye)
Karadeniz Technical University ( Site 2008)
Trabzon, , Turkey (Türkiye)
Bristol Haematology and Oncology Centre ( Site 2072)
Bristol, Bristol, City of, United Kingdom
ROYAL MARSDEN HOSPITAL (CHELSEA)-Lung Unit ( Site 2075)
London, Kensington and Chelsea, United Kingdom
St Bartholomews Hospital ( Site 2052)
London, London, City of, United Kingdom
Royal Free Hospital ( Site 2074)
London, London, City of, United Kingdom
Guys Hospital ( Site 2057)
London, London, City of, United Kingdom
Royal Marsden Hospital (Sutton) ( Site 2076)
London, London, City of, United Kingdom
Nottingham City Hospital ( Site 2058)
Nottingham, Nottinghamshire, United Kingdom
St James University Hospital ( Site 2055)
Leeds, , United Kingdom
Leicester Royal Infirmary ( Site 2051)
Leicester, , United Kingdom
The Christie NHS Foundation Trust ( Site 2066)
Manchester, , United Kingdom
The Clatterbridge Cancer Centre ( Site 2069)
Metropolitan Borough of Wirral, , United Kingdom
Queen Alexandra Hospital ( Site 2059)
Portsmouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-506327-29-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1293-5814
Identifier Type: REGISTRY
Identifier Source: secondary_id
INTerpath-009
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2061240105
Identifier Type: REGISTRY
Identifier Source: secondary_id
V940-009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.